Market Place
Sourcing Support
FDA Rejects Viatris, Mapi’s Long-Acting Multiple Sclerosis Injection
12 Mar 2024 //
BIOSPACE
Viatris and Mapi Pharma Announce FDA Acceptance of NDA Filing for GA Depot
07 Aug 2023 //
PR NEWSWIRE
Viatris and Mapi to Highlight Latest Results of Multiple Sclerosis Research
24 Apr 2023 //
PR NEWSWIRE
Mapi Pharma to Host a Key Opinion Leader Webinar on Glatiramer Acetate Depot
12 Oct 2022 //
GLOBENEWSWIRE
Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial
21 Sep 2022 //
GLOBENEWSWIRE
Mapi Pharma to Present Posters on GA Depot for Multiple Sclerosis at AAN
31 Mar 2022 //
GLOBENEWSWIRE
Mapi Pharma Receives Patent Covering Methods of Suppressing or Alleviating MS
30 Mar 2022 //
GLOBENEWSWIRE
Mapi Pharma Signs Agreement with Gaelan Medical Trade LLC
21 Oct 2021 //
GLOBENEWSWIRE
Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial
21 Dec 2020 //
GLOBENEWSWIRE
Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial
21 Dec 2020 //
PRESS RELEASE
Mapi Pharma, Mylan Expand MS Alliance
15 Jun 2020 //
CONTRACTPHARMA
Mapi Pharma raises $10M from Jingxin
08 Nov 2018 //
BIOSPECTRUM
Mapi Pharma swings for $50M haul as oft-delayed IPO nears D-Day
26 Jan 2016 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.